Biosurface Engineering Technologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://biosetinc.com
A Study Evaluating Amplex Compared To Autograft Bone In Foot and Ankle Fusion Surgery
Phase 1
- Conditions
- Arthritis
- Interventions
- Device: AmplexProcedure: Autograft bone
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- BioSurface Engineering Technologies, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01224119
- Locations
- 🇨🇦
Dr. Mark Glazebrook, Halifax, Nova Scotia, Canada
Pilot Study to Assess Safety/Prelimary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery
Phase 1
- Conditions
- Degenerative Disc DiseaseSpondylolisthesis
- Interventions
- Device: Prefix (AMPLEX) B2A Peptide Enhanced Ceramic GranulesOther: Iliac crest autograft
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- BioSurface Engineering Technologies, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00798239
- Locations
- 🇨🇦
Confidential, Montreal, Quebec, Canada
Pilot Study to Assess Safety/Preliminary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery
Phase 1
- Conditions
- Degenerative Disc DiseaseSpondylolisthesis
- Interventions
- Device: Prefix (AMPLEX) B2A Peptide Enhanced Ceramic GranulesOther: Iliac crest autograft
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- BioSurface Engineering Technologies, Inc
- Target Recruit Count
- 22
- Registration Number
- NCT00798902
- Locations
- 🇺🇸
Confidential, Tyler, Texas, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath